On Tuesday, the first act in the story of Donald Trump’s remarkable political resurrection comes to a close. The statewide contests in Virginia and New Jersey, as well as some other races around the ...

Hundreds of thousands of No Kings Day demonstrators are expected to take to the streets for what some believe will be the largest day of protest in modern U.S. history. Will historians remember it as ...

David George, Baird, joins 'Power Lunch' to discuss George's thoughts on Zions Bancorp, why the firm changed its rating and much more. BREAKING: Former Trump National Security Adviser John Bolton ...

Some players overperform and some underperform. That is just it rolls in fantasy football. Your top value plays this year have included Dak Prescott, Javonte Williams, Emeka Egbuka, and Jake Ferguson.

Market crashes aren't rare events; they're part of the normal investing cycle. History shows that 10% pullbacks happen almost yearly, 20% corrections every few years, and deeper 35%+ drawdowns roughly ...

The body urged Nigerian authorities to establish a rapid-response mechanism to verify refinery operations and product quality claims before misinformation spreads. Dangote is expecting Atmospheric ...

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational ...

Today’s horoscopes highlight a theme of deep personal and professional reassessment, urging the zodiac signs to embrace inner truth, set necessary boundaries, and carefully manage resources, according ...

World Financial Liberty (WLFI) traded at one point lower by more than 30%, extending a brutal multi-week sell-off that has erased nearly half of the token’s market cap. On Friday, October 10, the ...

Lloyds swaps Cazenove Capital stake for Schroders' joint venture stake Wealth venture rebranded as Lloyds Wealth Schroders to manage assets under new multi-year agreement with Lloyds Under the ...

Novo Nordisk is acquiring Akero Therapeutics for up to $5.2bn, aiming to diversify beyond semaglutide and strengthen its position in MASH and cirrhosis. The deal brings Akero's EFX, a promising FGF21 ...